Company Overview of Avantor Performance Materials, Inc.
Avantor Performance Materials, Inc. manufactures and markets high-performance chemistries and materials. It offers amino acids, chemical acids, aqueous solutions, biological buffers, biological reagents, chromatography media and columns, chromatography solvents, denaturants, electronic chemicals (acids, bases, and solvents), excipients, molecular biology reagents, chemical salts, semiconductor advanced front-end-of-line surface preparation products, solvents, stains and dyes, chemical sugars, surfactants and detergents, greener alternatives, and chemical vitamins and minerals; hematology, histopathology, and clinical chemistry products; and photoresist strippers, anti-reflective coatings, an...
3477 Corporate Parkway
Center Valley, PA 18034
Founded in 1867
Key Executives for Avantor Performance Materials, Inc.
Chief Executive Officer and President
Chief Financial & Administrative Officer and Executive Vice President
Executive Vice President and General Counsel
Chief Human Resources Officer and Executive Vice President
Compensation as of Fiscal Year 2013.
Avantor Performance Materials, Inc. Key Developments
Hagens Berman Adds Five Cases to Thalidomide Litigation
Aug 13 13
Hagens Berman Sobol Shapiro LLP has filed a new case on behalf of five alleged victims of multiple German and North American companies, charging that they or their predecessors concealed the distribution of the drug thalidomide to pregnant women in the 1960s, allegedly causing birth defects across the United States. The suit, filed on Aug. 7, 2013, brings the number of clients Hagens Berman represents to 49. The firm first brought attention to this matter when it filed its first lawsuit in 2011. The most recent filing in state court in Pennsylvania names Avantor Performance Materials, GlaxoSmithKline, Sanofi-Aventis and Grünenthal GmbH as defendants, as well as some of their subsidiaries. According to court documents, recent research suggests that thalidomide--a drug that caused thousands of horrific cases of deformities in children--caused far more deformities in the U.S. than originally thought. Invented by German drug company Grunenthal, thalidomide was widely used throughout Europe during the late 1950s and early 1960s, resulting in thousands of deaths and extreme, disfiguring birth defects when used by women during pregnancy. The drug was never approved for commercial distribution in the United States, but the new lawsuit filed now by HBSS on behalf of five individuals--all born with severe birth defects--alleges that as many as 2.5 million doses of thalidomide were distributed by more than 1,200 doctors to more than 20,000 people on U.S. soil, including pregnant women. The lawsuit is the latest in a series of suits filed by individuals who claim that their mothers were in the womb, and who suffered serious injuries or birth defects as a result. According to Berman, researchers initially concluded that thalidomide causes bilateral birth defects, such as two missing or shortened arms or hearing loss in both ears. As a result, babies born with unilateral defects, such as one deformed limb or hearing loss in only one ear, were not deemed thalidomide victims, even when their mothers were given the drug while pregnant. The lawsuit claims new research involving thalidomide as part of a treatment regimen in cancer patients casts doubt on the theory that the drug can only cause bilateral defects. The complaint claims that the defendants are either guilty of or liable for a civil conspiracy, failing to report and covering up evidence that thalidomide was harmful, especially when taken during the early stages of pregnancy. The lawsuit also says that the defendants were negligent in continuing to manufacture, test and distribute the drug. Hagens Berman is seeking punitive damages against the defendants on behalf of the plaintiffs, as well as compensation due to economic losses and emotional distress from physical defects.
Avantor Performance Materials, Inc. Names Richard White Executive Vice President of Operations
Sep 18 12
Avantor Performance Materials, Inc. announced the appointment of Richard White as executive vice president of operations. White will be responsible for Avantor's global manufacturing, enterprise resource planning, quality assurance, supply chain, and environmental health and safety (EHS) operations. He has more than 25 years of experience in global manufacturing, plant management, quality assurance, supply chain management, EHS, and other aspects of industrial operations -- especially in the chemicals and materials industry. Most recently, he served as chief operating officer for the Solar division at STR Holdings, Inc.
Avantor Performance Materials, Inc. Announces Executive Changes
Aug 20 12
Avantor Performance Materials, Inc. announced the appointment of John M. Steitz as president and chief executive officer. Steitz assumes the role of president and CEO from Avantor Chairman Rajiv L. Gupta, who had been serving as the company's CEO. Gupta remains chairman of the board of Avantor, which is owned by an affiliate of New Mountain Capital. Most recently, Steitz served as president and chief operating officer at Albemarle Corporation. In his role as president and CEO, Steitz will oversee all aspects of Avantor's global operations in its four business areas: Laboratory Products, Pharmaceuticals, Electronic Materials and Diagnostics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|